Chakraborty A, et al. (2011) Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. Proc Natl Acad Sci U S A 108, 2205-9 21262846

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S347-p - IHPK2 (human) ▲

Modsite: RPEVVLDsDAEDLED SwissProt Entrez-Gene Orthologous residues IHPK2 (human): S347‑p, IHPK2 iso4 (human): ‑, IHPK2 (mouse): S369‑p, IHPK2 (rat): S346‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical), U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes TBB decrease Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination

S356-p - IHPK2 (human) ▲

Modsite: AEDLEDLsEEsADES SwissProt Entrez-Gene Orthologous residues IHPK2 (human): S356‑p, IHPK2 iso4 (human): ‑, IHPK2 (mouse): S378‑p, IHPK2 (rat): S355‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site, western blotting Disease tissue studied:  bone cancer Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical), U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes TBB decrease Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination